Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen
After ∼4 years, DOR-based regimens were not associated with changes in ASCVD risk scores in PLWH. Given the increased burden of HIV-associated ASCVD, DOR may represent a therapeutic option that does not increase ASCVD risk.
Authors
- Georg M. N. Behrens (ORCID: https://orcid.org/0000-0003-3111-621X)
- Priscilla Y. Hsue (ORCID: https://orcid.org/0000-0002-3427-6043)
- Rima Lahoulou
- Rafael Campo
- Rebeca M. Plank (ORCID: https://orcid.org/0009-0009-4976-0792)
- Zhi Jin Xu (ORCID: https://orcid.org/0000-0002-5916-1605)
- Yujie Zhao (ORCID: https://orcid.org/0000-0003-2896-4955)
- John C’mar
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- UCLA Health (US)
- Medizinische Hochschule Hannover (DE)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1097/qai.0000000000003778
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00